191 related articles for article (PubMed ID: 14711304)
1. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
[TBL] [Abstract][Full Text] [Related]
2. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
3. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.
Wendt MD; Geyer A; McClellan WJ; Rockway TW; Weitzberg M; Zhao X; Mantei R; Stewart K; Nienaber V; Klinghofer V; Giranda VL
Bioorg Med Chem Lett; 2004 Jun; 14(12):3063-8. PubMed ID: 15149645
[TBL] [Abstract][Full Text] [Related]
4. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
5. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
6. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
7. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
8. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
[TBL] [Abstract][Full Text] [Related]
9. Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.
Bruncko M; McClellan WJ; Wendt MD; Sauer DR; Geyer A; Dalton CR; Kaminski MA; Weitzberg M; Gong J; Dellaria JF; Mantei R; Zhao X; Nienaber VL; Stewart K; Klinghofer V; Bouska J; Rockway TW; Giranda VL
Bioorg Med Chem Lett; 2005 Jan; 15(1):93-8. PubMed ID: 15582418
[TBL] [Abstract][Full Text] [Related]
10. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
Grembecka J; Mucha A; Cierpicki T; Kafarski P
J Med Chem; 2003 Jun; 46(13):2641-55. PubMed ID: 12801228
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
Renatus M; Bode W; Huber R; Stürzebecher J; Stubbs MT
J Med Chem; 1998 Dec; 41(27):5445-56. PubMed ID: 9876114
[TBL] [Abstract][Full Text] [Related]
12. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.
Lucas S; Heim R; Negri M; Antes I; Ries C; Schewe KE; Bisi A; Gobbi S; Hartmann RW
J Med Chem; 2008 Oct; 51(19):6138-49. PubMed ID: 18763754
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Bhongade BA; Gouripur VV; Gadad AK
Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
[TBL] [Abstract][Full Text] [Related]
14. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
15. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
Yang SQ; Craik CS
J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity.
Sieńczyk M; Oleksyszyn J
Bioorg Med Chem Lett; 2006 Jun; 16(11):2886-90. PubMed ID: 16546384
[TBL] [Abstract][Full Text] [Related]
17. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
[TBL] [Abstract][Full Text] [Related]
18. Species specificity of amidine-based urokinase inhibitors.
Klinghofer V; Stewart K; McGonigal T; Smith R; Sarthy A; Nienaber V; Butler C; Dorwin S; Richardson P; Weitzberg M; Wendt M; Rockway T; Zhao X; Hulkower KI; Giranda VL
Biochemistry; 2001 Aug; 40(31):9125-31. PubMed ID: 11478879
[TBL] [Abstract][Full Text] [Related]
19. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
[TBL] [Abstract][Full Text] [Related]
20. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
